6-Keto-ωaryl-PGE1 compounds
DESCRIPTION 
     CROSS REFERENCE TO RELATED APPLICATION 
     This application is a divisional application of co-pending application Ser. No. 829,679 filed Sept. 2, 1977, now pending issuance; which is a continuation-in-part of Ser. No. 755,675, filed Dec. 30, 1976, now abandoned. 
    
    
     BACKGROUND OF THE INVENTION 
     The present invention relates to novel 6-keto- ω-aryl-PGE 1  compounds which are useful agents for the induction of prostacyclin-like pharmacological effects. Accordingly, these compounds are useful for pharmacological purposes for which prostacyclin and related substances are employed. The essential material constituting disclosure of the preparation and use of these novel compounds is incorporated here by reference from Ser. No. 829,679, filed Sept. 2, 1977. 
     SUMMARY OF THE INVENTION 
     The present invention particularly provides a compound of the formula ##STR1## wherein W 1  is α-OH:β-H, α-H:β-OH, α-H:β-H, methylene, or α-CH 2  OH:β-H; 
     wherein R 3  is 
     (a) hydrogen, 
     (b) alkyl of one to 12 carbon atoms, inclusive. 
     (c) cycloalkyl of 3 to 10 carbon atoms, inclusive, 
     (d) aralkyl of 7 to 12 carbon atoms, inclusive, 
     (e) phenyl, 
     (f) phenyl substituted with one, 2 or 3 chloro or alkyl of one to 4 carbon atoms, inclusive, 
     (g) p-[p-(acetamido)benzamido]phenyl, 
     (h) p-(benzamido)phenyl, 
     (i) p-(acetamido)phenyl, 
     (j) p-hydroxyphenylurea, 
     (k) p-hydroxybenzaldehyde semicarbazone, 
     (l) β-naphthyl, 
     (m) -CH(R 11 )-CO-R 10 . 
     wherein Q is keto, α-H:β-H,α-OH:β-R 8 , or α-R 8  :β-OH, wherein R 8  is hydrogen, methyl or ethyl. 
     wherein R 5  and R 6  are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R 5  and R 6  is fluoro only when the other is hydrogen or fluoro and the further proviso that neither R 5  nor R 7  is fluoro when Z is oxa (--O--). wherein Z represents an oxa atom (--O--) or C j  H 2j  wherein C j  H 2j  is a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive between CR 5  R 6  -- and the (PH); wherein (PH) is phenyl or phenyl substituted by (T)s, 
     wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR 7--   wherein R 7  is alkyl of one to 4 carbon atoms, inclusive, and 
     wherein s is zero, one, 2 or 3, with the proviso that not more than two T&#39;s are other than alkyl and when s is 2 or 3 the T&#39;s are either the same or different; 
     wherein X is 
     (1) trans--CH═CH-- 
     (2) cis--CH═CH-- 
     (3) --C.tbd.C-- or 
     (4) --CH 2  CH 2  -- 
     wherein D is 
     (1) --(CH 2 ) d  --C(R 2 ) 2  -- 
     (2) --CH 2  --O--CH 2  --Y-- or 
     (3) --CH 2  CH═CH-- wherein d is zero to 5, R 2  is hydrogen, methyl or fluoro, being the same or different with the proviso that one R 2  is not methyl when the other is fluoro, and Y is a velence bond, --CH 2--   or --(CH 2 ) 2-- , and the pharmacologically acceptable salts thereof when R 3  is hydrogen. 
     With regard to the divalent substituents described above, e.g., Q and W 1 , these divalent radicals are defined as α-R i  :β-R j , wherein R i  represents a substituent of the divalent moiety of the alpha configuration with respect to the cyclopentane ring and R j  represents a substituent of the divalent moiety of the beta configuration with respect to the cyclopentane ring. Accordingly, when Q is defined as α-OH:β-R 8 , the hydroxy of the Q moiety is in the alpha configuration, i.e. as in prostacyclin, and th R 8  substituent is in the alpha configuration. Not all carbon atoms to which such divalent moieties are attached represent asymmetric centers. For example, when both valence bonds are to hydrogen, (e.g., W 1  or Q is α-H:β-H), then no asymmetric center is present. 
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     The present invention particularly relates to the following chemical compounds: 
     16phenoxy-17, 18, 19, 20-tetranor-6,15-diketo-PGE 1  ; 
     16-phenoxy-17,18,19,20-tetranor-6-keto-PGE 1  ; 
     6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1  ; 
     6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1  ; 
     6keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , p-phenylphenacyl ester; 
     6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , p-(acetamidobenzamido)phenyl ester; 
     6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , p-benzaldehyde semicarbazone ester; 
     16,16-demethyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1  ; 
     16,16-dimethyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1  ; 
     16,16-diemthyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , p-phenylphenacyl ester; 
     16,16-dimethyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , p-(acetamidobenzamido)-phenyl ester; 
     16,16-dimethyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , p-benzaldehyde semicarbazone ester; 
     16-phenyl-17,18,19,20-tetranor-6-keto-PGE 1  ; 
     17-phenyl-18,19,20-trinor-6-keto-PGE 1  ; 
     15(S)-15-methyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1  ; 
     15(S)-15-methyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , a p-phenylphenacyl ester; 
     15(S)-15-methyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , p-(p-acetamidobenzamido)-phenyl ester; 
     15(S)-15-methyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , benzaldehyde semicarbazone ester; 
     15(R)-15-methyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1  ; 
     6-keto-13,14-didehydro-16-phenoxy-17,18,19,20-tetranor PGE 1  ; 
     6-keto-13,14-didehydro-(15R)-16-phenoxy-17,18,19,20-tetranor-PGE 1  ; 
     6-keto-13,14-dihydro-16-phenoxy-17,18,19,20-tetranor-PGE 1  ; 
     2,2-difluoro-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , methyl ester; 
     2,2-difluoro-16,16-dimethyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE.sub.1, methyl ester; 
     2,2-difluoro-(15S)-15-methyl-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE.sub.1, methyl ester; 
     2,2-difluoro-13,14-didehydro-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE.sub.1, methyl ester; and 
     2,2-difluoro-13,14-dihydro-6-keto-16-phenoxy-17,18,19,20-tetranor-PGE 1 , methyl ester.